Longitudinal Monitoring of Inflammatory Bowel Disease Using a Sweat Sensing Wearable Device (Sweat Sensor Study)
The Sweat Sensor Study at Mount Sinai aims to measure and monitor markers of inflammation and the immune system, such as C-reactive protein and calprotectin, continuously in the sweat using a wearable sweat sensing device. Our hope is that this wearable device will even...
Age: 18 years - 66+
Gender: All
The Women With Inflammatory Bowel Disease and Motherhood (WIsDoM) Study - A Study Focused on Female Fertility and IBD
View WIsDoM Study Promo Video
What is the purpose of the study?
Many patients with Crohn’s disease or ulcerative colitis are women who are diagnosed with the disease during peak childbearing years. Both patients and providers frequently ask whether IBD, IBD...
Age: 18 - 45 years
Gender: Female
Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation
and bleeding from the lining of the rectum and colon (large intestine). This study will
assess how safe and effective Upadacitinib is in treating pediatric participants with UC.
...
Age: 2 - 17 years
Gender: All
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis
The main purpose of this study is to investigate efficacy, pharmacokinetics and safety of
the drug in pediatric participants with moderately to severely active ulcerative colitis
(UC).
Age: 2 - 17 years
Gender: All
ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2
This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and
safety of ABX464 given at 25 or 50 mg QD in inducing clinical remission in subjects with
moderately to severely active ulcerative colitis who have inadequate response, no
respons...
Age: 16 years - 66+
Gender: All
A Long-term Extension Study of Ustekinumab in Pediatric Participants
The purpose of this study is to collect long-term safety data of subcutaneous (SC)
ustekinumab
Age: 2 - 17 years
Gender: All
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
The main purpose of this study is to evaluate the long-term efficacy of mirikizumab in
pediatric participants with ulcerative colitis (UC) or Crohn's disease (CD). The study
will last about 172 weeks and may include up to 44 visits.
Age: 2 - 19 years
Gender: All
Study to Evaluate Safety, Tolerability and Efficacy of Oral E-B-FAHF-2 in Mild-to-Moderate Crohn's Disease
Crohn's disease (CD) is the major form of inflammatory bowel disease (IBD) affecting adults.
It is a life-long disease characterized by chronic and relapsing inflammation of the
gastrointestinal tract. CD has multiple clinical phenotypes and disease severities that
...
Age: 18 - 30 years
Gender: All
A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis
The purpose of this study is to evaluate the efficacy and safety of mirikizumab as
maintenance therapy in participants who completed prior 12-week induction study AMAN
(NCT03518086).
Age: 18 - 80 years
Gender: All
A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease
TARGET-IBD is a 5-year, longitudinal, observational study of adult and pediatric patients
(age 2 and above) being managed for Inflammatory Bowel Disease (IBD) in usual clinical
practice. TARGET-IBD will create a research registry of patients with IBD within academic
...
Age: 2 years - 66+
Gender: All
OMEGA: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages
The purpose of this observational study is to find the best measures to define how well a
person with eosinophilic disorder is doing. People with EoE, EoG, EoN and EoC normally
undergo endoscopy and/or colonoscopy where cells are collected for microscopic analysis.
T...
Age: 3 years - 66+
Gender: All
A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in
patients with moderately to severely active UC who are treated as recommended in the product
label.
Age: 18 - 99 years
Gender: All